This Week In Cannabis: Gaetz's Stock Rally, Major Policy Battles, Homeland Security's Stance, Big Earnings And More
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 28 2025
0mins
Source: Benzinga
Regulatory Developments: Florida's appeals court upheld a $1.3 million medical cannabis license renewal fee, while Virginia's Governor vetoed a cannabis sales bill for the second time, delaying the state's market launch. New York expanded its cannabis farmers market program to support licensed businesses amidst ongoing regulatory challenges.
Market Trends and Business Updates: Cannabis sales in Canada dropped 14.9% in January, while Ohio's cannabis industry surpassed $2.5 billion in total sales. Companies like Planet 13 and iAnthus reported revenue growth but also faced net losses, highlighting the volatility and evolving landscape of the cannabis market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 6.240
Low
8.50
Averages
9.57
High
10.00
Current: 6.240
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. It operates through four segments: cannabis operations, beverage operations, distribution operations, and the wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The beverage operations, which encompasses the production, marketing and of beverage products. The distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers. The Wellness products, which encompasses wellness and better-for-you foods and beverages. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, Chowie Wowie and others. It supports over 40 brands in over 20 countries, including cannabis offerings, hemp-based foods and craft beverages.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cannabis Edibles Market Experiences Rapid Growth
- Market Size Projections: The global cannabis edibles market is expected to reach approximately $7.1 billion by 2025 and climb to around $16.6 billion by 2030, indicating a strong growth trajectory driven by consumer demand for cleaner, more discreet consumption methods.
- Successful International Export: Herbal Dispatch has successfully completed its first export of medical cannabis gummies to Australia, generating approximately $350,000 in revenue, marking a significant milestone in the company's international growth strategy and reinforcing its position as a trusted supplier in the global medical cannabis market.
- Product Diversification Strategy: Herbal Dispatch is actively expanding its gummies and edibles offerings domestically under the Chomp brand, responding to strong consumer demand across both medical and recreational channels, highlighting the company's focus on convenient, dose-controlled formats to drive long-term growth.
- Emerging Investment Opportunities: With potential U.S. federal reform and the ongoing expansion of medical programs globally, the cannabis edibles market is positioned at the intersection of several powerful trends, likely capturing a larger market share and driving revenue diversification in high-growth categories.
See More
AKAN Stock Surges Following Marijuana Reclassification
- Stock Performance: Since the marijuana reclassification, AKAN stock has significantly outperformed peers Tilray, Canopy Growth, and Aurora Cannabis, which have seen declines of 8%, 4%, and 8% respectively, while AKAN surged 32%.
- Market Reaction: In the latest pre-market trading, AKAN shares surged 32%, marking its fourth-largest single-day gain this year, reflecting strong market confidence in its future growth potential.
- Policy Impact: The U.S. Department of Justice's reclassification of medical marijuana as a less dangerous drug is expected to ease regulatory burdens on licensed operators, provide tax relief, and support research, driving AKAN's strong performance.
- Retail Trader Sentiment: Over the past 30 days, message volume for AKAN on Stocktwits has skyrocketed by over 106,200%, indicating extremely bullish sentiment among retail investors, with many predicting the stock could reach triple digits.
See More
Trump Advocates for Marijuana Rescheduling
- Tax Relief Impact: Following the rescheduling of marijuana to Schedule III, U.S. companies like Curaleaf Holdings, Green Thumb Industries, and Trulieve Cannabis will benefit from tax reductions, allowing them to claim more expenses and thereby enhance profitability.
- Canadian Companies Limited: Canadian firms such as Tilray Brands are largely unaffected by the rescheduling due to the federal ban preventing them from selling marijuana products in the U.S., highlighting the need for investors to avoid misconceptions about the implications.
- Market Reaction Volatility: Although Tilray's stock surged 14% on the rescheduling news, it subsequently fell due to a lack of growth catalysts, reflecting market concerns about its future prospects, with a year-to-date decline of 27%.
- Investment Risk Advisory: Investors should exercise caution in making decisions based solely on marijuana reform news, as not all cannabis stocks will benefit equally, emphasizing the importance of understanding the full context before investing.
See More
Tilray: Value Trap or Value Stock?
- Poor Stock Performance: Tilray's shares have plummeted over 95% in the past five years, which, despite the company's market leadership and improving balance sheet, has deterred some investors, indicating market concerns about its future prospects.
- Valuation Metrics Analysis: With a price-to-book ratio of 0.54, Tilray appears cheap; however, approximately half of its book value ($752 million) consists of goodwill, which has been significantly written off in the past, raising concerns about its future valuation stability.
- Inconsistent Profitability: While Tilray ranks first in the Canadian adult-use cannabis market, its profitability has been inconsistent and it has consistently reported losses, reflecting the company's vulnerability amid changing market dynamics, particularly during periods of supply-demand imbalance.
- Potential Catalyst: The U.S. is in the process of reclassifying marijuana, which could lift IRS Section 280E restrictions, allowing Tilray to deduct most business expenses, potentially leading to significant financial improvements if successfully implemented.
See More
Analysis of Tilray Brands' 95% Stock Plunge
- Stock Plunge: Tilray Brands' shares have plummeted over 95% in the past five years, causing panic among some investors while others see a potential rebound opportunity; however, cheap stocks can often be value traps.
- Valuation Analysis: Despite a trailing P/E ratio of 57.5, Tilray's price-to-book ratio stands at 0.54, indicating a seemingly attractive valuation, yet half of its book value is goodwill, which the company has previously written off, posing future risks.
- Profitability Issues: Tilray has shown inconsistent profitability and has been consistently losing money; while it ranks first in the Canadian adult-use cannabis market, the oversupply in the market has driven prices down, negatively impacting its financial outlook.
- Potential Catalyst: The U.S. is in the process of reclassifying marijuana, which could lift IRS Section 280E restrictions, potentially improving Tilray's financials; if successful, this could lead to significant growth opportunities in the coming years.
See More
Meta Strikes Major Chip Deal with AWS to Enhance AI Infrastructure
- Infrastructure Investment: Meta has signed a three-year deal with AWS to deploy hundreds of thousands of Graviton chips, aiming to enhance AI performance with an expected 60% better energy efficiency than traditional systems, showcasing Meta's strategic commitment to AI.
- Workforce Adjustment: Despite the massive infrastructure investment, Meta announced a 10% workforce reduction, indicating a shift in capital allocation from human resources to high-performance silicon, reflecting the company's focus on future technology demands.
- Intensifying Market Competition: This move by Meta comes as competitors like Alphabet and Microsoft accelerate their internal hardware development, highlighting the urgency for Meta to secure computing capacity, which could reshape the industry landscape.
- CPU Renaissance: Intel has noted that central processors are re-emerging as the foundation for AI, and Meta's choice of Graviton chips over specialized accelerators indicates confidence in general-purpose processors, potentially driving growth across the semiconductor sector.
See More
Cannabis Edibles Market Experiences Rapid Growth
- Market Size Projections: The global cannabis edibles market is expected to reach approximately $7.1 billion by 2025 and climb to around $16.6 billion by 2030, indicating a strong growth trajectory driven by consumer demand for cleaner, more discreet consumption methods.
- Successful International Export: Herbal Dispatch has successfully completed its first export of medical cannabis gummies to Australia, generating approximately $350,000 in revenue, marking a significant milestone in the company's international growth strategy and reinforcing its position as a trusted supplier in the global medical cannabis market.
- Product Diversification Strategy: Herbal Dispatch is actively expanding its gummies and edibles offerings domestically under the Chomp brand, responding to strong consumer demand across both medical and recreational channels, highlighting the company's focus on convenient, dose-controlled formats to drive long-term growth.
- Emerging Investment Opportunities: With potential U.S. federal reform and the ongoing expansion of medical programs globally, the cannabis edibles market is positioned at the intersection of several powerful trends, likely capturing a larger market share and driving revenue diversification in high-growth categories.
See More
AKAN Stock Surges Following Marijuana Reclassification
- Stock Performance: Since the marijuana reclassification, AKAN stock has significantly outperformed peers Tilray, Canopy Growth, and Aurora Cannabis, which have seen declines of 8%, 4%, and 8% respectively, while AKAN surged 32%.
- Market Reaction: In the latest pre-market trading, AKAN shares surged 32%, marking its fourth-largest single-day gain this year, reflecting strong market confidence in its future growth potential.
- Policy Impact: The U.S. Department of Justice's reclassification of medical marijuana as a less dangerous drug is expected to ease regulatory burdens on licensed operators, provide tax relief, and support research, driving AKAN's strong performance.
- Retail Trader Sentiment: Over the past 30 days, message volume for AKAN on Stocktwits has skyrocketed by over 106,200%, indicating extremely bullish sentiment among retail investors, with many predicting the stock could reach triple digits.
See More
Trump Advocates for Marijuana Rescheduling
- Tax Relief Impact: Following the rescheduling of marijuana to Schedule III, U.S. companies like Curaleaf Holdings, Green Thumb Industries, and Trulieve Cannabis will benefit from tax reductions, allowing them to claim more expenses and thereby enhance profitability.
- Canadian Companies Limited: Canadian firms such as Tilray Brands are largely unaffected by the rescheduling due to the federal ban preventing them from selling marijuana products in the U.S., highlighting the need for investors to avoid misconceptions about the implications.
- Market Reaction Volatility: Although Tilray's stock surged 14% on the rescheduling news, it subsequently fell due to a lack of growth catalysts, reflecting market concerns about its future prospects, with a year-to-date decline of 27%.
- Investment Risk Advisory: Investors should exercise caution in making decisions based solely on marijuana reform news, as not all cannabis stocks will benefit equally, emphasizing the importance of understanding the full context before investing.
See More
Tilray: Value Trap or Value Stock?
- Poor Stock Performance: Tilray's shares have plummeted over 95% in the past five years, which, despite the company's market leadership and improving balance sheet, has deterred some investors, indicating market concerns about its future prospects.
- Valuation Metrics Analysis: With a price-to-book ratio of 0.54, Tilray appears cheap; however, approximately half of its book value ($752 million) consists of goodwill, which has been significantly written off in the past, raising concerns about its future valuation stability.
- Inconsistent Profitability: While Tilray ranks first in the Canadian adult-use cannabis market, its profitability has been inconsistent and it has consistently reported losses, reflecting the company's vulnerability amid changing market dynamics, particularly during periods of supply-demand imbalance.
- Potential Catalyst: The U.S. is in the process of reclassifying marijuana, which could lift IRS Section 280E restrictions, allowing Tilray to deduct most business expenses, potentially leading to significant financial improvements if successfully implemented.
See More
Analysis of Tilray Brands' 95% Stock Plunge
- Stock Plunge: Tilray Brands' shares have plummeted over 95% in the past five years, causing panic among some investors while others see a potential rebound opportunity; however, cheap stocks can often be value traps.
- Valuation Analysis: Despite a trailing P/E ratio of 57.5, Tilray's price-to-book ratio stands at 0.54, indicating a seemingly attractive valuation, yet half of its book value is goodwill, which the company has previously written off, posing future risks.
- Profitability Issues: Tilray has shown inconsistent profitability and has been consistently losing money; while it ranks first in the Canadian adult-use cannabis market, the oversupply in the market has driven prices down, negatively impacting its financial outlook.
- Potential Catalyst: The U.S. is in the process of reclassifying marijuana, which could lift IRS Section 280E restrictions, potentially improving Tilray's financials; if successful, this could lead to significant growth opportunities in the coming years.
See More
Meta Strikes Major Chip Deal with AWS to Enhance AI Infrastructure
- Infrastructure Investment: Meta has signed a three-year deal with AWS to deploy hundreds of thousands of Graviton chips, aiming to enhance AI performance with an expected 60% better energy efficiency than traditional systems, showcasing Meta's strategic commitment to AI.
- Workforce Adjustment: Despite the massive infrastructure investment, Meta announced a 10% workforce reduction, indicating a shift in capital allocation from human resources to high-performance silicon, reflecting the company's focus on future technology demands.
- Intensifying Market Competition: This move by Meta comes as competitors like Alphabet and Microsoft accelerate their internal hardware development, highlighting the urgency for Meta to secure computing capacity, which could reshape the industry landscape.
- CPU Renaissance: Intel has noted that central processors are re-emerging as the foundation for AI, and Meta's choice of Graviton chips over specialized accelerators indicates confidence in general-purpose processors, potentially driving growth across the semiconductor sector.
See More
